A meta‑analysis of the added value of diffusion weighted imaging in combination with contrast‑enhanced magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma lesser or equal to 2 cm

Lan, Hailong; Lin, Guangyu; Zhong, Weizhi

doi:10.3892/ol.2020.11805

Cited by 9 publications

(4 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies with WB-DWI showed a significantly higher sensitivity for cancer treatment assessment than those without (0.94 vs. 0.55, p = 0.02 at univariate metaregression and p = 0.012 at multivariate meta-regression). This is not surprising since DWI is a multipotent imaging modality for cancer diagnosis (30), staging (31), and treatment response assessment (32). Previous studies showed that ADC value increased significantly in responders compared to nonresponders (5,33).…”

Section: Discussionmentioning

confidence: 99%

Whole-Body MRI Is an Effective Imaging Modality for Hematological Malignancy Treatment Response Assessment: A Systematic Review and Meta-Analysis

Lin

Zong

et al. 2022

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

ObjectivesTo evaluate the diagnostic accuracy of whole-body MRI (WB-MRI) for assessment of hematological malignancies’ therapeutic response.MethodsPubMed, Embase, and Web of Science were searched up to August 2021 to identify studies reporting the diagnostic performance of WB-MRI for the assessment of hematological malignancies’ treatment response. A bivariate random-effects model was applied for the generation of the pooled diagnostic performance.ResultsFourteen studies with 457 patients with lymphoma, multiple myeloma, and sarcoma (very small proportion) were analyzed. Overall pooled sensitivity and specificity of WB-MRI were 0.88 (95% CI: 0.73–0.95) and 0.86 (95% CI: 0.73–0.93), respectively. Studies using whole-body diffusion-weighted imaging (WB-DWI) showed higher sensitivity than those that did not (0.94 vs. 0.55, p = 0.02). The pooled concordance rate of WB-MRI to assess hematological malignancies’ treatment response with reference standard was 0.78 (95% CI: 0.59–0.96). WB-MRI and PET/CT showed similar diagnostic performance (sensitivity [0.83 vs. 0.92, p = 0.11] and specificity [0.87 vs. 0.76, p = 0.73]).ConclusionWB-MRI has high diagnostic performance for hematological malignancies’ treatment response assessment. The adding of WB-DWI is strongly associated with increased sensitivity.

show abstract

Section: Discussionmentioning

confidence: 99%

Whole-Body MRI Is an Effective Imaging Modality for Hematological Malignancy Treatment Response Assessment: A Systematic Review and Meta-Analysis

Lin

Zong

et al. 2022

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…DWI offers functional quantitative data on the tissue's microstructure by means of the water proton mobility differences and cellular density evaluation. Water diffusion mobility is linked to cell density, vascularity and viscosity of the extracellular apparent diffusion coefficient (ADC), and it's possible to identify imaging biomarkers for fibrosis, tumor fluid and cell membrane integrity using a mono-exponential model or with diffusion and perfusion parameters in a bi-exponential model [104][105][106][107][108][109][110][111][112][113][114]. Using an Intravoxel Incoherent Motion method (IVIM) bi-exponential model to analyze DWI data, it is possible to obtain the pure tissue coefficient (Dt) linked only to diffusion water mobility, the pseudo-diffusion coefficient (Dp) linked to blood mobility, and the perfusion fraction (fp) [115][116][117][118][119][120][121][122].…”

Section: Diffusion Weighted Imaging-mrimentioning

confidence: 99%

Diagnostic evaluation and ablation treatments assessment in hepatocellular carcinoma

Granata

Grassi

Fusco³

et al. 2021

Infect Agents Cancer

View full text Add to dashboard Cite

This article provides an overview of diagnostic evaluation and ablation treatment assessment in Hepatocellular Carcinoma (HCC). Only studies, in the English language from January 2010 to January 202, evaluating the diagnostic tools and assessment of ablative therapies in HCC patients were included. We found 173 clinical studies that satisfied the inclusion criteria.HCC may be noninvasively diagnosed by imaging findings. Multiphase contrast-enhanced imaging is necessary to assess HCC. Intravenous extracellular contrast agents are used for CT, while the agents used for MRI may be extracellular or hepatobiliary. Both gadoxetate disodium and gadobenate dimeglumine may be used in hepatobiliary phase imaging. For treatment-naive patients undergoing CT, unenhanced imaging is optional; however, it is required in the post treatment setting for CT and all MRI studies. Late arterial phase is strongly preferred over early arterial phase. The choice of modality (CT, US/CEUS or MRI) and MRI contrast agent (extracelllar or hepatobiliary) depends on patient, institutional, and regional factors. MRI allows to link morfological and functional data in the HCC evaluation. Also, Radiomics is an emerging field in the assessment of HCC patients.Postablation imaging is necessary to assess the treatment results, to monitor evolution of the ablated tissue over time, and to evaluate for complications. Post- thermal treatments, imaging should be performed at regularly scheduled intervals to assess treatment response and to evaluate for new lesions and potential complications.

show abstract

“…DWI shows diffusion restriction in areas of high cellularity and cell membrane density (for example, malignancy) (27). DWI increases the sensitivity of conventional extracellular contrast-enhanced MRI, especially for small (<2 cm) HCCs (28). Sensitivity for HCC with gadoxetic acid contrastenhanced MRI is improved (95.2%) when including wash-out criteria for the hepatobiliary phase (29).…”

Section: Hepatocellular Carcinomamentioning

confidence: 99%

Radiologic-Pathologic Correlation of Liver Tumors

et al. 2021

View full text Add to dashboard Cite

Radiologic and pathologic features of common and/or critical tumor or tumor-like diagnoses (lesions) of the liver are discussed within. Hepatocellular lesions (focal nodular hyperplasia, hepatocellular adenoma, hepatocellular carcinoma, and hepatoblastoma), biliary lesions (mucinous cystic neoplasm and intrahepatic cholangiocarcinoma), vascular mesenchymal lesions (cavernous hemangioma, epithelioid hemangioendothelioma, and hepatic angiosarcoma), and metastatic malignancies are the primary focus, although a more comprehensive list of lesions is also provided. Definitions, distributions, gross appearances and microscopic pathological features are introduced first, followed by radiologic correlation. Multiple imaging modalities are explored with an emphasis on those that provide the greatest value for the lesion under evaluation. A common understanding of the features of both diagnostic specialties will allow for high-quality correlation and subsequent high-quality patient care. Representative images highlighting important features are also presented.

show abstract

A meta‑analysis of the added value of diffusion weighted imaging in combination with contrast‑enhanced magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma lesser or equal to 2 cm

Cited by 9 publications

References 39 publications

Whole-Body MRI Is an Effective Imaging Modality for Hematological Malignancy Treatment Response Assessment: A Systematic Review and Meta-Analysis

Whole-Body MRI Is an Effective Imaging Modality for Hematological Malignancy Treatment Response Assessment: A Systematic Review and Meta-Analysis

Diagnostic evaluation and ablation treatments assessment in hepatocellular carcinoma

Radiologic-Pathologic Correlation of Liver Tumors

Contact Info

Product

Resources

About